论文部分内容阅读
目的探讨白三稀受体拮抗剂治疗支气管哮喘临床效果。方法 2009年1月至2010年3月门诊或住院的支气管哮喘168例,随机分为白三稀受体拮抗剂组88例和常规治疗组80例,观察两组肺功能改善情况。结果白三稀受体拮抗剂组在治疗4周后无哮喘症状天数明显减少,自觉临床症状改善明显由治疗前的(13.6±8.5)d,减少为(52.6±10.8)d。两组治疗后肺功能测定比较(P<0.05),差异有统计学意义。结论白三烯受体拮抗剂顺尔宁具有应用方便、长期临床效果显著、安全可靠、毒副作用少等优点,可作为支气管哮喘治疗中常规应用药物。
Objective To investigate the clinical effect of leukotriene receptor antagonist in the treatment of bronchial asthma. Methods From January 2009 to March 2010, 168 outpatients or hospitalized patients with bronchial asthma were randomly divided into three groups: 88 patients treated with antihypertensive agents and 80 patients treated with conventional therapy. The improvement of pulmonary function was observed in both groups. Results Compared with the control group, the number of days without asthma symptoms decreased significantly after 4 weeks of treatment. The improvement of clinical symptoms was significantly reduced from (13.6 ± 8.5) days before treatment to (52.6 ± 10.8) days. The lung function of the two groups after treatment were compared (P <0.05), the difference was statistically significant. CONCLUSIONS: Leukotriene receptor antagonist Shundening has the advantages of convenient application, long-term clinical effect, safety and reliability, less side effects and the like, and can be used as a routine medicine for the treatment of bronchial asthma.